S. 1096Introduced
Preserve Access to Affordable Generics and Biosimilars Act
Prohibits anticompetitive patent settlement agreements involving brand name drugs, generics, and biosimilars, with FTC enforcement and agreement certification requirements
Plain-English overview
What this bill does
Prohibits anticompetitive patent settlement agreements involving brand name drugs, generics, and biosimilars, with FTC enforcement and agreement certification requirements
Key points
- Require agreement certifications
- Prohibit anticompetitive patent settlements
- Authorize FTC enforcement
Current status
Where it stands
Status
Introduced
Latest action
2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
Related context
Topics and policy areas
undefinedAdministrative law and regulatory proceduresCivil actions and liabilityCompetition and antitrustContracts and agencyFederal Trade Commission (FTC)HealthIntellectual property